Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.
CITATION STYLE
Chen, Z. R., Zhou, Y., Liu, J., Peng, H. W., Zhou, J., Zhong, H. L., … Wen, J. H. (2020, June 24). Pharmacotherapics Advice in Guidelines for COVID-19. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2020.00950
Mendeley helps you to discover research relevant for your work.